Phase III clinical trial - Sein Adjuvant

NATALEE (CLEE011O12301C)
Sein Adjuvant
Ouvert depuis le: 10.22.2020
Site: Paris
Ouvert depuis le: 08.01.2019
Site: Saint-Cloud
Public cible
Adulte
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negartive Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Description de l'essai

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer